Citius Pharmaceuticals, Inc. (CTXR)
| Previous close | 0.7070 |
| Open | 0.7300 |
| Bid | 0.7062 x 200 |
| Ask | 0.7232 x 200 |
| Day's range | 0.7000 - 0.7300 |
| 52-week range | 0.6000 - 1.4500 |
| Volume | |
| Avg. volume | 899,427 |
| Market cap | 129.164M |
| Beta (5Y monthly) | 1.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2600 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCitius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has closed its previously announced registered direct offering for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase up to an aggregate of 21,428,574 shares of its common stock, at a purchase price of $0.70 per sha
- PR Newswire
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase up to an aggregate of 21,428,574 shares of its common stock, at a purchase price of $0.70 per share and accompanying warr
- PR Newswire
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas. The ongoing study, led by Dr. Veronika Bachanova at the U
